ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Doença de vias aéreas associada à artrite reumatoide.[Carta]: comportamento longitudinal da função pulmonar (2024)
Sabbag, Maria Laura Bertozo; Molina, Camila de Assis; Sawamura, Marcio Valente Yamada; Bonfiglioli, Karina; Medeiros-Ribeiro, Ana Cristina; Pugliesi, Alisson; Nakagawa, Renato Hideo; Arimura, Fabio Eiji; Athanazio, Rodrigo Abensur; Kairalla, Ronaldo Adib
Source: Jornal brasileiro de pneumologia. Unidade: FM
Subjects: ARTRITE REUMATOIDE, PULMÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABBAG, Maria Laura Bertozo et al. Doença de vias aéreas associada à artrite reumatoide.[Carta]: comportamento longitudinal da função pulmonar. Jornal brasileiro de pneumologia. Brasilia DF: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/76882. Acesso em: 02 nov. 2025. , 2024
APA
Sabbag, M. L. B., Molina, C. de A., Sawamura, M. V. Y., Bonfiglioli, K., Medeiros-Ribeiro, A. C., Pugliesi, A., et al. (2024). Doença de vias aéreas associada à artrite reumatoide.[Carta]: comportamento longitudinal da função pulmonar. Jornal brasileiro de pneumologia. Brasilia DF: Faculdade de Medicina, Universidade de São Paulo. doi:10.36416/1806-3756/e20230322
NLM
Sabbag MLB, Molina C de A, Sawamura MVY, Bonfiglioli K, Medeiros-Ribeiro AC, Pugliesi A, Nakagawa RH, Arimura FE, Athanazio RA, Kairalla RA. Doença de vias aéreas associada à artrite reumatoide.[Carta]: comportamento longitudinal da função pulmonar [Internet]. Jornal brasileiro de pneumologia. 2024 ; 50( 1):[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76882
Vancouver
Sabbag MLB, Molina C de A, Sawamura MVY, Bonfiglioli K, Medeiros-Ribeiro AC, Pugliesi A, Nakagawa RH, Arimura FE, Athanazio RA, Kairalla RA. Doença de vias aéreas associada à artrite reumatoide.[Carta]: comportamento longitudinal da função pulmonar [Internet]. Jornal brasileiro de pneumologia. 2024 ; 50( 1):[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76882
Artigo de periodico
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis (2022)
Medeiros-Ribeiro, Ana Cristina; Bonfiglioli, Karina Rossi; Domiciano, Diogo Souza; Shimabuco, Andrea Yukie; Silva, Henrique Carrico da; Saad, Carla G. S.; Yuki, Emily Figueiredo Neves; Pasoto, Sandra Gofinet; Araujo, Carlo Scognamiglio Renner; Nakai, Tatiane Lie; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Kallas, Esper Georges ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ESTUDOS PROSPECTIVOS, SISTEMA IMUNE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEDEIROS-RIBEIRO, Ana Cristina et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the rheumatic diseases, v. 81, n. 5, p. 710-719, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-221735. Acesso em: 02 nov. 2025.
APA
Medeiros-Ribeiro, A. C., Bonfiglioli, K. R., Domiciano, D. S., Shimabuco, A. Y., Silva, H. C. da, Saad, C. G. S., et al. (2022). Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the rheumatic diseases, 81( 5), 710-719. doi:10.1136/annrheumdis-2021-221735
NLM
Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva HC da, Saad CGS, Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 5): 710-719.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221735
Vancouver
Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva HC da, Saad CGS, Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 5): 710-719.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221735
Artigo de periodico
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial (2022)
Araujo, Carlo Scognamiglio Renner; Medeiros-Ribeiro, Ana Cristina; Saad, Carla G. S; Bonfiglioli, Karina Rossi; Domiciano, Diogo Souza; Shimabuco, Andrea Yukie; Kupa, Leonard de Vinci Kanda ; Pereira, Rosa Maria Rodrigues ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: METOTREXATO, VACINAS VIRAIS, ARTRITE REUMATOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, Carlo Scognamiglio Renner et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the rheumatic diseases, v. 81, n. 6, p. 889-897, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-221916. Acesso em: 02 nov. 2025.
APA
Araujo, C. S. R., Medeiros-Ribeiro, A. C., Saad, C. G. S., Bonfiglioli, K. R., Domiciano, D. S., Shimabuco, A. Y., et al. (2022). Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the rheumatic diseases, 81( 6), 889-897. doi:10.1136/annrheumdis-2021-221916
NLM
Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Kupa L de VK, Pereira RMR, Silva CAA da, Bonfa ESD de O. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 6): 889-897.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221916
Vancouver
Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Kupa L de VK, Pereira RMR, Silva CAA da, Bonfa ESD de O. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 6): 889-897.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221916
Artigo de periodico
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases (2022)
Aikawa, Nadia Emi; Kupa, Leonard de Vinci Kanda; Medeiros-Ribeiro, Ana Cristina; Saad, Carla Goncalves Schahin; Pereira, Rosa Maria Rodrigues ; Shinjo, Samuel Katsuyuki ; Sartori, Ana Marli Christovam ; Antonangelo, Leila ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: VACINAÇÃO, DOENÇAS AUTOIMUNES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AIKAWA, Nadia Emi et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, v. 81, n. 7, p. 1036-1043, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-222096. Acesso em: 02 nov. 2025.
APA
Aikawa, N. E., Kupa, L. de V. K., Medeiros-Ribeiro, A. C., Saad, C. G. S., Pereira, R. M. R., Shinjo, S. K., et al. (2022). Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, 81( 7), 1036-1043. doi:10.1136/annrheumdis-2021-222096
NLM
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Vancouver
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Artigo de periodico
SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy (2022)
Sampaio-Barros, Percival Degrava; Medeiros-Ribeiro, Ana Cristina; Luppino-Assad, Ana Paula; Miossi, Renata; Silva, Henrique Carrico da; Yuki, Emily F. V. N; Pasoto, Sandra G; Saad, Carla G. S; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Rheumatology. Unidade: FM
Subjects: PEDIATRIA, DOENÇAS NEONATAIS E ANORMALIDADES, ANTIBIÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAMPAIO-BARROS, Percival Degrava et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, v. 61, n. SI2, p. SI169-SI174, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab886. Acesso em: 02 nov. 2025.
APA
Sampaio-Barros, P. D., Medeiros-Ribeiro, A. C., Luppino-Assad, A. P., Miossi, R., Silva, H. C. da, Yuki, E. F. V. N., et al. (2022). SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 61( SI2), SI169-SI174. doi:10.1093/rheumatology/keab886
NLM
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1093/rheumatology/keab886
Vancouver
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1093/rheumatology/keab886
Artigo de periodico
Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients (2022)
Gualano, Bruno ; Lemes, Ítalo Ribeiro ; Silva, Rafael Pires da ; Pinto, Ana Jessica ; Mazzolani, Bruna Caruso ; Smaira, Fabiana Infante ; Sieczkowska, Sofia Mendes ; Aikawa, Nadia Emi ; Pasoto, Sandra Gofinet ; Medeiros-Ribeiro, Ana Cristina ; Saad, Carla; Yuki, Emily F. N ; Silva, Clovis Artur ; Swinton, Paul Alan ; Hallal, Pedro Curi ; Roschel, Hamilton ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Scandinavian journal of medicine & science in sports. Unidades: FM, EEFE
Subjects: DOENÇAS AUTOIMUNES, DOENÇAS REUMÁTICAS, COVID-19, IMUNOSSUPRESSÃO, ATIVIDADE FÍSICA, VACINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUALANO, Bruno et al. Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients. Scandinavian journal of medicine & science in sports, v. 32, n. 10, p. 1510-1515, 2022Tradução . . Disponível em: https://doi.org/10.1111/sms.14213. Acesso em: 02 nov. 2025.
APA
Gualano, B., Lemes, Í. R., Silva, R. P. da, Pinto, A. J., Mazzolani, B. C., Smaira, F. I., et al. (2022). Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients. Scandinavian journal of medicine & science in sports, 32( 10), 1510-1515. doi:10.1111/sms.14213
NLM
Gualano B, Lemes ÍR, Silva RP da, Pinto AJ, Mazzolani BC, Smaira FI, Sieczkowska SM, Aikawa NE, Pasoto SG, Medeiros-Ribeiro AC, Saad C, Yuki EFN, Silva CA, Swinton PA, Hallal PC, Roschel H, Bonfa ESD de O. Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients [Internet]. Scandinavian journal of medicine & science in sports. 2022 ; 32( 10): 1510-1515.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1111/sms.14213
Vancouver
Gualano B, Lemes ÍR, Silva RP da, Pinto AJ, Mazzolani BC, Smaira FI, Sieczkowska SM, Aikawa NE, Pasoto SG, Medeiros-Ribeiro AC, Saad C, Yuki EFN, Silva CA, Swinton PA, Hallal PC, Roschel H, Bonfa ESD de O. Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients [Internet]. Scandinavian journal of medicine & science in sports. 2022 ; 32( 10): 1510-1515.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1111/sms.14213

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Funding Agencies